GlassScriptPhysician profile
Mara Martinez
NPI 1578030714
$3,614.00
in general payments reported to CMS, 2019-2025
24 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,200 · 2022: $1,030 · 2023: $771 · 2024: $475 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $604.35 | 2021-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $532.81 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $317.30 | 2021-2023 | |
| Novo Nordisk INC | $316.26 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $249.47 | 2021-2024 | Nexletol |
| Mannkind Corporation | $245.19 | 2022-2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $212.08 | 2021 | |
| Abbvie INC. | $133.60 | 2021-2025 | |
| Astellas Pharma US INC | $124.55 | 2021-2022 | |
| Glaxosmithkline, LLC. | $118.10 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $109.54 | 2021-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.66 | 2022-2024 | Cycloset |
| Teva Pharmaceuticals USA, INC. | $80.24 | 2023-2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $62.78 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.48 | 2021-2022 | |
| Pfizer INC. | $52.20 | 2021-2024 | |
| Amarin Pharma, INC. | $49.52 | 2021 | |
| Althera Pharmaceuticals LLC | $43.76 | 2021-2022 | |
| Sanofi Pasteur INC. | $40.45 | 2022-2023 | |
| Dexcom, INC. | $26.55 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $14.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.